Acquisitions and Divestitures - Narrative (Details) $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions, ¥ in Billions						3 Months Ended					12 Months Ended
	Jan. 28, 2022 USD ($)	Oct. 01, 2020 USD ($)	Apr. 01, 2019 USD ($)	Jan. 17, 2019 USD ($)	Jan. 17, 2019 JPY (¥)	Oct. 03, 2021 USD ($)	Jan. 03, 2021 USD ($) $ / shares	Sep. 27, 2020 USD ($)	Mar. 29, 2020 USD ($)	Mar. 31, 2019 USD ($)	Jan. 02, 2022 USD ($) shares	Jan. 02, 2022 CHF (SFr) shares	Jan. 03, 2021 USD ($) $ / shares shares	Jan. 03, 2021 CHF (SFr) shares	Dec. 29, 2019 USD ($)	Jan. 03, 2021 CHF (SFr)	Jan. 16, 2019
Business Acquisition [Line Items]
Consideration transferred													$ 7,300
Liabilities assumed							$ 400						400		$ 1,400
Goodwill (Notes 1 and 5)							36,393				$ 35,246		36,393		33,639
Acquisitions, net of cash acquired											60		7,323		5,810
Other (income) expense, net											(489)		(2,899)		(2,525)
Contingent consideration liability							633				533		633
Long-term debt							34,434				32,116		34,434
In Process Research and Development
Business Acquisition [Line Items]
Impairment of intangible assets, excluding goodwill						$ 900		$ 100
2019 Acquisitions | In Process Research and Development
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired															6,800
Auris Health
Business Acquisition [Line Items]
Liabilities assumed			$ 1,800
Intangible assets assumed			$ 3,000
Discount rate			9.50%
Goodwill (Notes 1 and 5)			$ 2,000
Acquisitions, net of cash acquired			3,400
Contingent consideration liability			2,350				$ 1,100						$ 1,100
Marketable securities assumed			$ 200
Auris Health | In Process Research and Development
Business Acquisition [Line Items]
Impairment of intangible assets, excluding goodwill											900
Ci:z Holdings Co. Ltd.
Business Acquisition [Line Items]
Consideration transferred				$ 2,100	¥ 230.0
Liabilities assumed									$ 400
Intangible assets assumed									1,500
Goodwill (Notes 1 and 5)									1,200
Foreign currency exchange rate, translation																	109.06
Other (income) expense, net										$ 300
Weighted average useful life of acquired intangibles							15 years 3 months 18 days
Idorsia
Business Acquisition [Line Items]
Sale of stock, number of shares issued in transaction (in shares) | shares													11.8	11.8
Sale of stock, percentage of ownership before transaction													8.30%	8.30%
Proceeds from sale of equity interests													$ 357	SFr 337.0
Sale of stock (in USD per share) | $ / shares							$ 28.55						$ 28.55
Convertible note, equity Interest (in shares) | shares													38.7	38.7
Momenta
Business Acquisition [Line Items]
Consideration transferred		$ 6,100
Liabilities assumed		$ 1,600
Discount rate		13.00%
Goodwill (Notes 1 and 5)		$ 1,200
Other assets assumed		500
Momenta | In Process Research and Development
Business Acquisition [Line Items]
Intangible assets assumed		$ 6,000
2020 Acquisitions | In Process Research and Development
Business Acquisition [Line Items]
Purchase price over fair value of assets acquired							$ 7,500						$ 7,500
bermekimab
Business Acquisition [Line Items]
Consideration transferred									800
Intangible assets assumed									$ 800
Discount rate									16.00%
bermekimab | Subsequent Event
Business Acquisition [Line Items]
Impairment of intangible assets, excluding goodwill	$ 600
Verb Surgical Inc.
Business Acquisition [Line Items]
Liabilities assumed									$ 300
Intangible assets assumed									400
Goodwill (Notes 1 and 5)									200
Other assets assumed									200
Equity method investments, fair value									$ 400
Maximum | Auris Health
Business Acquisition [Line Items]
Probability of success factor			66.00%
Maximum | Momenta
Business Acquisition [Line Items]
Probability of success factor		77.00%
Maximum | bermekimab
Business Acquisition [Line Items]
Probability of success factor									60.00%
Minimum | Auris Health
Business Acquisition [Line Items]
Probability of success factor			18.00%
Minimum | Momenta
Business Acquisition [Line Items]
Probability of success factor		20.00%
Minimum | bermekimab
Business Acquisition [Line Items]
Probability of success factor									20.00%
Convertible Debt | Idorsia
Business Acquisition [Line Items]
Long-term debt | SFr																SFr 445.0
Convertible debt, amount of loan converted											$ 120	SFr 110.0
Convertible Debt, number of equity instruments (in shares) | shares											9.6	9.6
AdvancedSterilizationProducts
Business Acquisition [Line Items]
Gain (loss) on divestiture															2,000
Evra and Doxil
Business Acquisition [Line Items]
Proceeds from divestiture of brands											$ 600
Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts
Business Acquisition [Line Items]
Disposal group, including discontinued operation, consideration															2,800
Disposal group, including discontinued operation, cash															2,700
Disposal group, including discontinued operation, receivables retained															$ 100